SEQUENCE LISTING

- <110> Children's Medical Center Corporation Ashkar, Samy
- <120> Osteopontin-Coated Surfaces and Methods of Use
- <130> CMCC 779
- <150> US 60/241,248
- <151> 2000-10-18
- <150> US 60/327,273
- <151> 2001-10-05
- <160> 16
- <170> PatentIn version 3.1
- <210> 1
- <211> 314
- <212> PRT
- <213> Homo sapiens
- <400> 1
- Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala 1 5 10 15
- Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu 20 25 30
- Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro 35 40 45
- Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ala Val Ser Ser Glu 50 55 60
- Glu Thr Asn Asp Phe Lys Gln Glu Thr Leu Pro Ser Lys Ser Asn Glu 65 70 75 80
- Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp His 85 90 95

Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp
100 105 110

Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu
115 120 125

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu 130 135 140

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly 145 150 155 160

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg 165 170 175

Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His 180 185 190

Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala 195 200 205

Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser 210 215 220

Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His 225 230 235 240

Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu 245 250 255

His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu 260 265 270

Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp 275 280 285

```
Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser His
                                            300
    290
                        295
Glu Leu Asp Ser Ala Ser Ser Glu Val Asn
305
                    310
<210>
      2
<211>
<212> PRT
<213> Artificial Sequence
<220>
<223> Osteopontin-derived peptide
<400>
      2
Leu Val Leu Asp Pro Lys
                5
<210>
      3
<211>
<212> PRT
<213> Artificial Sequence
<220>
<223>
      Osteopontin fragment
<400> 3
Leu Val Val Asp Pro Lys
<210>
     4
<211>
      5
<212> PRT
<213>
      Artificial Sequence
<220>
<223> Artificial peptide sequence
<400>
      4
```

```
Arg Gly Arg Asp Ser
<210>
      5
<211>
      5
<212>
      PRT
<213> Artificial Sequence
<220>
<223>
      Artificial peptide sequence
<400>
Gly Arg Gly Asp Ser
<210>
<211>
      32
<212>
      PRT
<213>
      Artificial Sequence
<220>
       Artificial peptide sequence
<223>
<400>
       6
Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
1
                5
                                     10
                                                         15
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Phe Arg Arg
            20
                                25
<210>
       7
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
      Artificial peptide sequence
<223>
<400>
       7
Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
1
                5
                                     10
                                                         15
```

```
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg 20 25 30
```

Pro

<210> 8

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> · Artificial peptide sequence

<400> 8

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro 35 40

<210> 9

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial peptide sequence

<400> 9

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu 1 5 10 15

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly 20 25 30

```
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
35 40 45
```

Pro

```
<210> 10
```

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial peptide sequence

<400> 10

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro 35 40

<210> 11

<211> 63

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial peptide sequence

<400> 11

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser 20 25 30

```
Lys Ser Lys Lys Phe Arg Arg Pro Ala Gly Ala Ala Gly Gly Pro Ala 35 40 45
```

Gly Pro Ala Gly Pro Ala Gly Pro Ala Gly Pro Ala 50 55 60

<210> 12

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial peptide sequence

<400> 12

Arg Ser Arg Arg Val Phe Thr Pro Phe Ile Pro Thr Glu Ser Ala Asn 1 5 10 15

Asp Gly Arg Gly Asp Ser Val Ala Tyr Gly Leu Lys Ser Lys 20 25 30

Lys Phe Arg Arg 35

<210> 13

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial peptide sequence

<400> 13

Asp Thr Phe Thr Pro Ile Val Pro Thr Val Asp Val Pro Asn Gly Arg
1 10 15

Phe Asp Ser Leu Ala Tyr Gly Leu Lys Ser Lys Ser Lys Phe Gln 20 25 30

```
<210> 14
<211>
      40
<212>
      PRT
<213>
      Artificial Sequence
<220>
<223>
      Artificial peptide sequence
<400>
       14
Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
                                                         15
                5
                                     10
Asp Thr Tyr Asp Gly Arg Ala Asp Ser Val Val Tyr Gly Arg Arg Ser
                                                     30
                                 25
            20
Lys Ser Lys Lys Phe Arg Arg Pro
        35
                             40
<210>
       15
<211>
       40
<212>
       PRT
       Artificial Sequence
<213>
<220>
<223>
      Artificial peptide sequence
<220>
<221> MISC FEATURE
<222>
      (1)..(1)
<223> Acetyl-modified N-terminus
<400> 15
Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
                                                         15
                5
                                     10
Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser
```

25

30

20

Lys Ser Lys Lys Phe Arg Arg Pro 35 40

<210> 16

<211> 59

<212> PRT

<213> Artificial sequence

<220>

<223> Osteopontin fragment

<400> 16

Glu His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg 1 5 10 15

Glu Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val 20 25 30

Asp Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser 35 40 45

His Glu Leu Asp Ser Ala Ser Ser Glu Val Asn 50 55